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Introduction 
Asthma is a common medical problem in Pakistan. Allergic Bronchopulmonary Aspergillosis (ABPA),
an immune mediated disease, is an unusual complication of bronchial asthma which can result in
bronchiectasis, pulmonary fibrosis, respiratory failure and death. Early diagnosis is important so that
with proper therapy permanent lung damage can be prevented. First described in 19521, ABPA was
thought to be a rare disorder, but with increased awareness amongst the physicians and better
diagnostic techniques, äases are being recognized more frequently. The clinical features of ABPA
(cough, fever, hemoptysis and lung infiltrates) are usually mistaken for pulmonary tuberculosis (TB).
We present three cases in which failure to consider the diagnosis of ABPA resulted in repeated courses
of anti-TB therapy and/or progressive lung damage and continued morbidity.
Case reports 
Case 1: Recurrent hemoptysis and pulmonary infiltrates
A 19 year old male, asthmatic from childhood. developed fever, cough, hemoptysis and pulmonary
infiltrate in 1987. He was treated for TB fornine months. In 1992, he again presented with fever,
anorexia, cough, hemoptysis and patchy infiltration in left upper lobe (Figure la).
Sputum was negative for AFB but on clinical suspicion, he was restarted on quadruple anti-TB therapy
in adequate doses. In addition, he continued to receive bronchodilators, inhaled steroids and
intermittent courses of oral prednisolone. Six months later, while still on anti-TB drugs, he developed
recurrence of symptoms with right pleuritic chest pain, fever, cough, wheeze and hemoptysis. Repeat
chest x-ray showed infiltrates in right lung (Figure ib).
Sputum for AFB was negative. He had eosinophilia of 12% (WBC count 12600/dI) and 2grossly
elevated serum IgE (>1000 iu/ml). Aspergillus antibodies were negative. A diagnosis of ABPA was
made and prednisolone 30 mg daily was started. This resulted in rapid resolution of clinical and
radiological features. Patient remains well on maintenance prednisolone at a dose of 7.5 mg daily.
Case 2: Bilateral interstitial infiltrates and bronchicctasis
A 24 year old male, asthmatic for four years, presented with high grade fever, cough with purulent
sputum and right sided chest pain. He had two similar episodes during the last one year. Bilateral
widespread rhonchi and crepitation were found on chest examination. Chest x-ray showed bilateral
interstitial infiltrates and bronchiectatic changes. White cell count was 12700/dl with 33% eosinophils.
Sputa for AFB were negative. Patient improved partially with a course of Amoxicillin-Clavulanic Acid,
bronchodilators and physiotherapy but continued to be wheezy and dyspnoeic. Serum IgE was elevated
above 1000 lU/mi.
CT scan of the chest (Figure 2) revealed mucous impaction in the bronchi and central bronchiectasis.
He made a good response to oral steroid therapy.
Case 3: Migratory infiltrates and marked eosinophilia
This 28 year old lady gave two years history of recurrent cough, fever and wheeze. Symptoms
improved temporarily with the use of antibiotics and bronchodilators but recurred on stopping therapy.
She presented with relapse of her symptoms and was found to have bilateral wheeze. White cell count
was 24,800/di with marked eosinophilia of 60%. Chest x-ray showed infiltrates in left upper and right
middle zones. Her previous eosinophil counts varied from 40-60% and x-rays showed fleeting
pulmonary infiltrates. Serum IgE was elevated at 970 lU/mi. She made a rapid clinical and radiological
response tø oral steroid therapy and remained well one year after discha.rge.
Discussion 
Aspergillus fungus is widely distributed throughput the world and can involve the lung through a
number of diverse mechanisms. A. fumigatus is the most common pathogenic species, but other species
such as A. niger, A. flavus and A. terreus are also pathogenic in humans. Allergic broncho pulmonary
aspergillus (ABPA) is primarily an immune mediated disorder. It develops when aspergilus colonizes
the ainvays of a susceptible host and produces antigens. There is no tissue invasion by the fungus. Type
I (IgE mediated immediate hypersensitivity), Type Ill (IgG mediated immune complex) and Type IV
(cell mediated delayed hypersensitivity) responses have all been implicated in the disease process2,3.
These immune responses result in bronchospasm, increased permeability of bronchial mucosa,
pulmonary and blood eosinophiiia, chronic inflarnmation and bronchial destruction, bronchiectasis and
pulmonary fibrosis. Most patients with ABPA are very atopic and have asthma. The peak incidence of
ABPA is in the third and fourth decade of life4. Other allergic symptoms,’ such as. rhinitis,
conjunctivitis, urticaria. eczema, food ordrug allergy may also be present. In corticosteroid dependent
asthmatics prevalence of ABPA was found to be 7-14% in North America5 and 15-22% in Great
Britain6. In India, the prevalence of antibodies to Aspergillus among asthmatics was found to be 20%
by ELISA method7. The other conditions where ABPA occurs in up to 10% of patients is cystic
fibrosis8. The clinical features include cough. hemoptysis, expectoration of mucus plugs, dyspnoea,
fever, malaise, anorexia and pleuritic chest pain in an asthmatic patient9. Most of these features are
easily confused as TB and result in repeated courses of prolonged anti-TB therapy. Physician’s
awareness for ABPA is very low which results in delayed diagnosis and permanent lung damage. There
is no single pathognonionic test for ABPA but the diagnosis can be made by following Rosenberg and
Patterson’s criteria (Table). However, the serological markers may be absent during remission or when
the patient is on corticosteroids10. The patient may be followed for several years before all the
diagnostic criteria can be fulfilled11. Species of aspergillus other than A. fumigatus and fungi other than
aspergillus have also been reported to cause similar disease12 and in these cases the serological markers
for A. fumigatus would be negative Serial chest radiographs reveal fleeting pulmonary infiltrates
usually in the upper lobes13. Tramline, parallel line and ring shadows represent thickened bronchial
walls. The typical branching toothpaste and gloved finger shadows are due to mucous impaction.
Massive consolidation may be seen. Ateleclasis and pulmonary, fibrosis is less common.
Bronchography has been the gold standard for the diagnosis of brouchiectasis but high resolution CT
scan is equally sensitive for detection of bronchial wall changes14. The course of ABPA is marked by
recurrent episodes of reversible bronchial obstruction. Without early diagnosis and treatment, central
bronchiectasis, pulmonary fibrosis, respiratory failure and death may occur. Some of the other
conditions, characterised by pulmonary infiltrates, peripheral eosinophilia and elevated serum IgE
level, which need to be differentiated from ABPA are Loeffler’s syndrome, tropical pulmonary
eosinophilia, eosinophilic pneumonia, hypereosinophilic syndrome and Churg Strauss syndrome.
Systemic corticosteroids control acute exacerbation, prevent permanent lung damage and is the
treatment of choice15. Usual starting dose of 0.5 mg/kg/day is given for 2-3 weeks and then tapered
gradually over the next 6 months. High dose inhaled steroids can be beneficial and may help to
diminish the dose or duration of oral steroids16. Anti-fungal therapy had been in- effective in the
therapy of ABPA but recent studies with newer agents such as Itraconazole appear promising17.
Diagnosis of ABPA requires a high index of suspicion. It should be considered in asthmatics who
develop systemic symptoms, fleeting pulmonary shadows, eosinophilia and grossly elevated serum IgE
levels. Pulmonary TB should be ruled out by sputum examination and other diseases with pulmonary
infiltrates and eosinophilia need to be excluded. Early diagnosis and steroid therapy are crucial to
prevent irreversible lung damage and respiratory failure.
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